drugset / Trial / NCT06492408
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by delivery of CTLA4 and PD1 or PDL1 antibodies combination through CT-guided intra-tumor (IT) injection.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2028-12-30
- Completion
- 2033-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Other |
| Subject | Durvalumab | Monoclonal antibody | — | Other |
| Subject | Idarubicin | Small molecule | — | Other |
| Subject | Ipilimumab | Monoclonal antibody | — | Other |
| Subject | Pembrolizumab | Monoclonal antibody | — | Other |